Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate
To evaluate the preliminary efficacy of in reducing the frequency and severity of hot flashes in men on androgen deprivation therapy (ADT).
Prostate Adenocarcinoma
DRUG: Osanetant
To evaluate the preliminary efficacy of in reducing the frequency and severity of vasomotor symptoms (VMS) in men on androgen deprivation therapy (ADT)., Efficacy will be assessed using a composite outcome of median weekly hot flash frequency and severity at week 4 compared to baseline., 28 days
To evaluate the effect of Osanetant on follicle stimulating hormone for men with prostate cancer on ADT., Levels of follicle stimulating hormone (FSH) will be measured at week 4 will be compared to baseline., 28 days|To evaluate the effect of Osanetant on luteinizing hormone for men with prostate cancer on ADT., luteinizing hormone (LH) will be measured at week 4 will be compared to baseline., 28 days|To evaluate the effect of Osanetant on testosterone for men with prostate cancer on ADT., testosterone will be measured at week 4 will be compared to baseline., 28 days|To evaluate the effect of Osanetant on estradiol for men with prostate cancer on ADT., estradiol will be measured at week 4 will be compared to baseline. with prostate cancer on ADT, 28 days|Functional Assessment of Cancer Therapy-Prostate (FACT-P), To evaluate the impact of Osanetant on global quality of life with Functional Assessment of Cancer Therapy-Prostate (FACT-P), 28 days|EuroQOL 5-dimension, To evaluate the impact of Osanetant on global quality of life with a visual analog scale from EuroQOL 5-dimension, 5-level (EQ-5D-5L). The EQ-5D-5L visual analog scale is 0-100 with higher numbers being better., 28 days|Patient Health Questionnaire-9 question (PHQ-9)., To evaluate the impact of Osanetant on depressive symptoms on Patient Health Questionnaire-9 question (PHQ-9)., 28 days|General Anxiety Disorder-7 question (GAD-7), To evaluate the impact of Osanetant on anxiety symptoms on General Anxiety Disorder-7 question (GAD-7)., 28 days|Hot Flash Related Daily Interference Scale (HFRDIS)., To evaluate the impact of Osanetant on hot flash interference using the Hot Flash Related Daily Interference Scale (HFRDIS). The hot flash daily interference scale has a minimum of 0 and a max of 100, with higher scores indicating more interference (which is worse)., 28 days
To evaluate the preliminary efficacy of in reducing the frequency and severity of hot flashes in men on androgen deprivation therapy (ADT).